MCA Thumbnails 1 2 3
Alternative & Traditional Therapies

New App SI DOA Aims to Improve Traditional Home Medicine

Innovation in healthcare technology plays a crucial role in advancing patient care and treatment efficacy. Recently, a student from Politeknik Negeri Jember (Polije) has pioneered a groundbreaking solution in pharmaceutical technology with the development of the SI DOA application. 

MCA Thumbnails 6 3
Country

DOH-Bicol Achieves Remarkable 92% TB Treatment Success Rate

The Department of Health-Center for Health Development in Bicol (DOH CHD-5) announced a 92% treatment success rate for tuberculosis (TB) cases for Q1 2024. This achievement was highlighted during the “Kapihan sa Bagong Pilipinas” briefing held at the Bicol Medical Center in Naga City. This success is indicative of the region’s robust health initiatives and effective implementation of TB treatment protocols. 

MCA Thumbnails 1 16
Insurance

The Ultimate Guide: 37 Critical Illnesses in Singapore

For most Singaporeans, medical insurance is their primary protection from sickness. It shields them both financially and medically. A core component of medical insurance is critical illness.  In this article, guest writer Michael Seow gives a clearer understanding of what critical illness coverage provides.

MCA Thumbnails 1 4
Country

Polio Vaccination Campaign Underway in Jayapura

The first round of the polio vaccination campaign in Jayapura, Indonesia, has achieved remarkable success, reaching an 81.3% coverage rate. This accomplishment marks a significant step in the global fight against polio, particularly in regions with historically low vaccination rates. This article will explore the details of the campaign, its impact, and the broader implications for public health in Asia.

MCA Thumbnails 2 2 3
Cancer

Press Release – Roche’s Tecentriq® SC (atezolizumab) becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Singapore, reducing treatment time to a few minutes

Roche announced today that Tecentriq® SC (atezolizumab) has been approved by the Singapore Health Sciences Authority (HSA) for all indications in which the intravenous (IV) formulation of Tecentriq has been previously approved, including certain types of lung, breast and liver cancer.4 Tecentriq SC is Roche’s fourth subcutaneous cancer therapy,5-7 and the world’s first injectable anti-PD-(L)1 cancer immunotherapy.

Log In or Register as a healthcare professional to read the full article.

Copyright © Medical Channel Asia 2024. All rights reserved.
The contents on Medical Channel Asia are for general educational purposes only.
It is not intended to be a substitute for professional medical advice, treatment, or diagnosis.
See additional information.

Don’t have an account? Click here to register

[ultimatemember form_id="29399"]

If have account, Click here to login